• 1
    Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GNJ. Campylobacter pyloridis-associated gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 88: 3340.
  • 2
    Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 15258.
  • 3
    Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 5860.
  • 4
    Sipponen G. Gastric cancer—a long-term consequence of Helicobacter pylori infection? Scand J Gastroenterol 1994; 201: 247.
  • 5
    Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Society Award lecture on cancer epidemiology and prevention. Cancer Res 1992; 52: 673540.
  • 6
    Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113: 198391.
  • 7
    Lee A, Dixon MF, Danon SJ, et al. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur J Gastroenterol Hepatol 1995; 7: 4615.
  • 8
    El-Omar EM, Oien K, El-Nujumi A, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 1997; 113: 1524.
  • 9
    Logan RP, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 126.
  • 10
    Kuipers EJ, Lundell L, Klinkenberg-Knoll E, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 101822.
  • 11
    Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 70717.
  • 12
    Lundell L, Miettinen P, Myrvold HE, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999; 117: 31926.
  • 13
    Suzuki M, Miura S, Suematsu M, et al. Helicobacter pylori-associated ammonia production enhances neutrophil-dependent gastric mucosal injury. Am J Physiol 1992; 263: G71925.
  • 14
    Stockbrügger RW, Cotton PB, Menon GG, et al. Pernicious anaemia, intragastric bacterial overgrowth, and possible consequences. Scand J Gastroenterol 1984; 19: 35564.
  • 15
    Stockbrügger RW, Cotton PB, Eugenides N, Bartholomew BA, Hill MJ, Walters CL. Intragastric nitrites, nitrosamines and bacterial overgrowth during cimetidine treatment. Gut 1982; 23: 104854.
  • 16
    Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during and after treatment with omeprazole. Br Med J 1984; 289: 7179.
  • 17
    Verdu E, Viani F, Armstrong D, et al. Effect of omeprazole on intragastric bacterial counts, nitrates, and N-nitroso compounds. Gut 1994; 35: 45560.
  • 18
    Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared to cimetidine: a prospective randomized double blind study. Gut 1996; 39: 549.
  • 19
    Crabtree JE, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor and interleukin-6 in patients with Helicobacter pylori associated gastritis. Gut 1991; 32: 14734.
  • 20
    Ando T, Kusugami K, Ohsuga M, et al. Interleukin-8 activity correlates with histological severity in Helicobacter pylori-associated antral gastritis. Am J Gastroenterol 1996; 91: 11506.
  • 21
    Gionchetti P, Vaira D, Campieri M, et al. Enhanced mucosal interleukin-6 and interleukin-8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol1994; 883–7.
  • 22
    Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 94553.
  • 23
    Sartor RB, Rath HC, Sellon RK. Microbial factors in chronic intestinal inflammation. Curr Opin Gastroenterol 1996; 12: 32733.
  • 24
    Jonkers D, Stobberingh E, De Bruine A, Arends JW, Stockbrügger RW. Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies. J Infection 1997; 35: 14954.
  • 25
    Jonkers D, Gisbertz I, De Bruine A, et al. Helicobacter pylori and non-Helicobacter pylori bacterial flora in gastric mucosal and tumour specimens of patients with primary gastric lymphoma. Eur J Clin Invest 1997; 27: 88592.
  • 26
    Jonkers D, Houben P, Hameeteman W, et al. Differential features of gastric cancer patients, either Helicobacter pylori positive or Helicobacter pylori negative. Ital J Gastroenterol Hepatol 1999; 31: 83641.
  • 27
    Price AB. The Sydney System: Histological division. J Gastroenterol Hepatol 1991; 6: 20922.
  • 28
    Dixon M, Genta R, Yardley J, Correa P. Classification and grading of gastritis. The updated Sydney system. Am J Surg Pathol 1996; 20: 116181.
  • 29
    Genta RM. Recognizing atrophy: another step toward a classification of gastritis. Am J Surg Pathol 1996; 20(Suppl. 1): S2330.
  • 30
    Andrew W, Wyatt JI, Dixon MF. Observer variation in the assessment of chronic gastritis according to the Sydney system. Histopathology 1994; 25: 31722.
  • 31
    Kleinbaum DG, Kupper LL, Muller KE. Applied Regression Analysis and Other Multivariate Methods. Boston: PBS-Kent publ. Co, 1988.
  • 32
    Rothman K. Modern Epidemiology. Boston: Little, Brown, 1986.
  • 33
    Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high-risk population: cohort follow-up. Cancer Res 1990; 50: 473740.
  • 34
    Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Scand J Gastroenterol 1996; 31: 54650.
  • 35
    Oksanen A, Sipponen P, Karttunen R, et al. Atrophic gastritis and Helicobacter pylori infection in outpatients referred for gastroscopy. Gut 2000; 46: 4603.
  • 36
    Verdu E, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori on intragastric pH during treatment with omeprazole. Gut 1995; 36: 53943.
  • 37
    Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrügger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther 2001; 15(3): 37988.DOI: 10.1046/j.1365-2036.2001.00888.x
  • 38
    Mowat C, Williams C, Gillen D, et al. Omeprazole,Helicobacter pylori status and alterations in intragastric milieu facilitating bacterial N-nitrosation. Gastroenterology 2000; 119: 33947.
  • 39
    El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398402.DOI: 10.1038/35006081
  • 40
    Birkholz S, Knipp U, Nietzki C, et al. Immunological activity of lipopolysaccharide of Helicobacter pylori on human peripheral blood cells in comparison to lipopolysaccharides of other intestinal bacteria. FEMS Immunol Med Microbiol 1993; 6: 31724.
  • 41
    Perez-Perez GI, Sheperd VI, Morrow JD, Blaser MJ. Activation of human THP-1 cells and rat bone marrow-derived macrophages by Helicobacter pylori lipopolysaccharide. Infect Immun 1995; 63: 11837.
  • 42
    Baume PE, Nicholls A, Baxter CH. Inhibition of gastric acid secretion by a purified bacterial lipopolysaccharide. Nature 1967; 215: 5960.
  • 43
    Kondo S, Shinomura Y, Kanayama S, et al. Interleukin-1 beta inhibits gastric histamine secretion and synthesis in the rat. Am J Physiol 1994; 267: G96671.
  • 44
    Yasunaga Y, Shinomura Y, Kanayama S, et al. Mucosal interleukin-1 beta production and acid secretion in enlarged fold gastritis. Aliment Pharmacol Ther 1997; 11: 8019.
  • 45
    McColl KE, El-Omar EM, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998; 54: 12138.